SE0202241D0 - Novel Compounds - Google Patents

Novel Compounds

Info

Publication number
SE0202241D0
SE0202241D0 SE0202241A SE0202241A SE0202241D0 SE 0202241 D0 SE0202241 D0 SE 0202241D0 SE 0202241 A SE0202241 A SE 0202241A SE 0202241 A SE0202241 A SE 0202241A SE 0202241 D0 SE0202241 D0 SE 0202241D0
Authority
SE
Sweden
Prior art keywords
novel compounds
relates
present
pharmaceutical compounds
respiratory disorders
Prior art date
Application number
SE0202241A
Other languages
English (en)
Swedish (sv)
Inventor
Simon Teague
Hitesh Sanganee
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0202241A priority Critical patent/SE0202241D0/xx
Publication of SE0202241D0 publication Critical patent/SE0202241D0/xx
Priority to SE0203713A priority patent/SE0203713D0/xx
Priority to TW092118486A priority patent/TW200404778A/zh
Priority to NZ537606A priority patent/NZ537606A/en
Priority to AU2003251260A priority patent/AU2003251260B2/en
Priority to EP03764279A priority patent/EP1551802B1/en
Priority to AT03764279T priority patent/ATE450506T1/de
Priority to JP2004521364A priority patent/JP4791729B2/ja
Priority to DK03764279.0T priority patent/DK1551802T3/da
Priority to CNB038199718A priority patent/CN1279023C/zh
Priority to SI200331737T priority patent/SI1551802T1/sl
Priority to CA002492445A priority patent/CA2492445A1/en
Priority to PCT/SE2003/001216 priority patent/WO2004007451A1/en
Priority to MXPA05000646A priority patent/MXPA05000646A/es
Priority to DE60330372T priority patent/DE60330372D1/de
Priority to US10/521,325 priority patent/US7723373B2/en
Priority to ES03764279T priority patent/ES2335491T3/es
Priority to PT03764279T priority patent/PT1551802E/pt
Priority to BR0312729-0A priority patent/BR0312729A/pt
Priority to AR20030102585A priority patent/AR040498A1/es
Priority to IL16612105A priority patent/IL166121A0/xx
Priority to ZA200500170A priority patent/ZA200500170B/xx
Priority to NO20050828A priority patent/NO20050828L/no
Priority to CY20101100086T priority patent/CY1109760T1/el
Priority to US12/758,348 priority patent/US20100197756A1/en
Priority to JP2010166138A priority patent/JP2010280680A/ja
Priority to JP2011043693A priority patent/JP2011116770A/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
SE0202241A 2002-07-17 2002-07-17 Novel Compounds SE0202241D0 (sv)

Priority Applications (27)

Application Number Priority Date Filing Date Title
SE0202241A SE0202241D0 (sv) 2002-07-17 2002-07-17 Novel Compounds
SE0203713A SE0203713D0 (sv) 2002-07-17 2002-12-13 Novel compounds
TW092118486A TW200404778A (en) 2002-07-17 2003-07-07 Novel compounds
BR0312729-0A BR0312729A (pt) 2002-07-17 2003-07-15 Novos derivados de indol-3-enxofre
PCT/SE2003/001216 WO2004007451A1 (en) 2002-07-17 2003-07-15 Indole-3-sulphur derivatives
DE60330372T DE60330372D1 (de) 2002-07-17 2003-07-15 Indol-3-schwefelderivate
EP03764279A EP1551802B1 (en) 2002-07-17 2003-07-15 Indole-3-sulphur derivatives
AT03764279T ATE450506T1 (de) 2002-07-17 2003-07-15 Indol-3-schwefelderivate
JP2004521364A JP4791729B2 (ja) 2002-07-17 2003-07-15 インドール−３−硫黄誘導体
DK03764279.0T DK1551802T3 (da) 2002-07-17 2003-07-15 Indol-3-svovlderivater
CNB038199718A CN1279023C (zh) 2002-07-17 2003-07-15 吲哚－3－硫衍生物
SI200331737T SI1551802T1 (sl) 2002-07-17 2003-07-15 Indol žveplovi derivati
CA002492445A CA2492445A1 (en) 2002-07-17 2003-07-15 Indole-3-sulphur derivatives
NZ537606A NZ537606A (en) 2002-07-17 2003-07-15 Indole-2-sulphur derivatives and their use to treat prostaglandin D2 mediated diseases
MXPA05000646A MXPA05000646A (es) 2002-07-17 2003-07-15 Derivados de indol-3-azufre.
AU2003251260A AU2003251260B2 (en) 2002-07-17 2003-07-15 Indole-3-sulphur derivatives
US10/521,325 US7723373B2 (en) 2002-07-17 2003-07-15 Indole-3-sulphur derivatives
ES03764279T ES2335491T3 (es) 2002-07-17 2003-07-15 Derivados de indol-3-azufre.
PT03764279T PT1551802E (pt) 2002-07-17 2003-07-15 Derivados de indole-3-enxofre
AR20030102585A AR040498A1 (es) 2002-07-17 2003-07-17 Indoles sustituidos utiles para el tratamiento de enfermedades respiratorias
IL16612105A IL166121A0 (en) 2002-07-17 2005-01-03 Indole-3-sulphur derivatives
ZA200500170A ZA200500170B (en) 2002-07-17 2005-01-07 Indole-3-sulphur derivatives.
NO20050828A NO20050828L (no) 2002-07-17 2005-02-16 lndol-3-svovelderivater
CY20101100086T CY1109760T1 (el) 2002-07-17 2010-01-28 Παραγωγα ινδολης-3-θειου
US12/758,348 US20100197756A1 (en) 2002-07-17 2010-04-12 Indole-3-Sulphur Derivatives
JP2010166138A JP2010280680A (ja) 2002-07-17 2010-07-23 インドール−３−硫黄誘導体
JP2011043693A JP2011116770A (ja) 2002-07-17 2011-03-01 インドール−３−硫黄誘導体

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0202241A SE0202241D0 (sv) 2002-07-17 2002-07-17 Novel Compounds
SE0203713A SE0203713D0 (sv) 2002-07-17 2002-12-13 Novel compounds

Publications (1)

Publication Number Publication Date
SE0202241D0 true SE0202241D0 (sv) 2002-07-17

Family

ID=30117585

Family Applications (2)

Application Number Title Priority Date Filing Date
SE0202241A SE0202241D0 (sv) 2002-07-17 2002-07-17 Novel Compounds
SE0203713A SE0203713D0 (sv) 2002-07-17 2002-12-13 Novel compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
SE0203713A SE0203713D0 (sv) 2002-07-17 2002-12-13 Novel compounds

Country Status (23)

Country Link
US (2) US7723373B2 (el)
EP (1) EP1551802B1 (el)
JP (3) JP4791729B2 (el)
CN (1) CN1279023C (el)
AR (1) AR040498A1 (el)
AT (1) ATE450506T1 (el)
AU (1) AU2003251260B2 (el)
BR (1) BR0312729A (el)
CA (1) CA2492445A1 (el)
CY (1) CY1109760T1 (el)
DE (1) DE60330372D1 (el)
DK (1) DK1551802T3 (el)
ES (1) ES2335491T3 (el)
IL (1) IL166121A0 (el)
MX (1) MXPA05000646A (el)
NO (1) NO20050828L (el)
NZ (1) NZ537606A (el)
PT (1) PT1551802E (el)
SE (2) SE0202241D0 (el)
SI (1) SI1551802T1 (el)
TW (1) TW200404778A (el)
WO (1) WO2004007451A1 (el)
ZA (1) ZA200500170B (el)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) * 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
SE0301010D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
SE0301569D0 (sv) * 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
US7348338B2 (en) 2003-07-17 2008-03-25 Plexxikon, Inc. PPAR active compounds
KR20130023381A (ko) 2003-07-17 2013-03-07 플렉시콘, 인코퍼레이티드 Ｐｐａｒ 활성 화합물
SE0302232D0 (sv) 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
US20070232681A1 (en) * 2003-10-14 2007-10-04 Oxagen Limited Compounds Having Crth2 Antagonist Activity
SE0303180D0 (sv) * 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
US7714132B2 (en) 2004-03-11 2010-05-11 Actelion Pharmaceuticals, Ltd. Tetrahydropyridoindole derivatives
GB0412914D0 (en) * 2004-06-10 2004-07-14 Oxagen Ltd Compounds
MY144903A (en) * 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
GB0415320D0 (en) 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
GB0418830D0 (en) 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
JP5063348B2 (ja) * 2004-08-26 2012-10-31 アクテリオン ファーマシューティカルズ リミテッド ２−スルファニル−ベンゾイミダゾール−１−イル−酢酸誘導体
CA2581338A1 (en) 2004-09-21 2006-03-30 Athersys, Inc. Indole acetic acids exhibiting crth2 receptor antagonism and uses thereof
PT1809602E (pt) * 2004-10-27 2008-12-15 Janssen Pharmaceutica Nv Derivados de indole úteis como moduladores do receptor da progesterona
PT1817282E (pt) 2004-11-23 2011-09-19 Astrazeneca Ab Derivados do ácido fenoxiacético úteis para tratar doenças respiratórias
US7531568B2 (en) * 2004-11-30 2009-05-12 Plexxikon, Inc. PPAR active compounds
US20060135540A1 (en) * 2004-11-30 2006-06-22 Jack Lin PPAR active compounds
NZ556657A (en) 2004-12-27 2010-10-29 Actelion Pharmaceuticals Ltd 2,3,4,9-tetrahydro-1H-carbazole derivatives as CRTH2 receptor antagonists
GB0500604D0 (en) * 2005-01-13 2005-02-16 Astrazeneca Ab Novel process
MX2007010112A (es) * 2005-02-25 2007-10-12 Ono Pharmaceutical Co Compuesto indol y uso del mismo.
GB0505048D0 (en) * 2005-03-11 2005-04-20 Oxagen Ltd Compounds with PGD antagonist activity
EP1911759A4 (en) 2005-07-22 2010-07-21 Shionogi & Co AZAINDOL DERIVATIVE ANTAGONISTIC EFFECT ON PGD2 RECEPTOR
EP1916245B1 (en) 2005-07-22 2011-10-26 Shionogi & Co., Ltd. Indole derivative having pgd2 receptor antagonist activity
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
GT200600407A (es) * 2005-09-07 2007-04-10 Compuestos ppar activos
EP1931658A2 (en) * 2005-09-07 2008-06-18 Plexxikon, Inc. 1 , 4 and 1 , 5-disubstituted indole derivatives for use as ppar active compounds
TW200745003A (en) 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
US8148572B2 (en) 2005-10-06 2012-04-03 Astrazeneca Ab Compounds
GB0525143D0 (en) 2005-12-09 2006-01-18 Novartis Ag Organic compounds
GB0526257D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
WO2007138282A2 (en) 2006-05-26 2007-12-06 Astrazeneca Ab Bi-aryl or aryl-heteroaryl substituted indoles
EP2037967B1 (en) 2006-06-16 2016-12-07 The Trustees Of The University Of Pennsylvania Prostaglandin d2 receptor antagonists for treating androgenetic alopecia
KR20090042808A (ko) 2006-07-22 2009-04-30 옥사겐 리미티드 씨알티에이치2 길항제 활성을 갖는 화합물
NZ574705A (en) 2006-08-07 2011-12-22 Actelion Pharmaceuticals Ltd (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetic acid derivatives
PE20090159A1 (es) * 2007-03-08 2009-02-21 Plexxikon Inc COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs
UA100983C2 (ru) 2007-07-05 2013-02-25 Астразенека Аб Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
GB0722055D0 (en) * 2007-11-09 2007-12-19 Argenta Discovery Ltd Compounds
SI2229358T1 (sl) 2007-12-14 2011-10-28 Pulmagen Therapeutics Asthma Ltd Indoli in njihova terapevtska uporaba
CN101932571B (zh) * 2008-01-18 2014-04-23 奥克萨根有限公司 具有crth2拮抗活性的化合物
US7750027B2 (en) * 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
EP2265581A1 (en) 2008-01-22 2010-12-29 Oxagen Limited Compounds having crth2 antagonist activity
EP2240444A1 (en) 2008-01-22 2010-10-20 Oxagen Limited Compounds having crth2 antagonist activity
TWI469965B (zh) 2008-12-22 2015-01-21 Ono Pharmaceutical Co 乙炔基吲哚化合物
MX2012000229A (es) * 2009-07-06 2012-01-25 Astrazeneca Ab Intermediarios y procesos para preparar el acido 4-(acetilamino)-3-[(4-clorofenil)tio]-2-metil-1h-indol-1-acetico.
WO2011055270A1 (en) 2009-11-04 2011-05-12 Wyeth Llc Indole based receptor crth2 antagonists
UY33110A (es) 2009-12-23 2011-07-29 Ironwood Pharmaceuticals Inc Moduladores de CRTH2
WO2011115804A1 (en) 2010-03-17 2011-09-22 Ironwood Pharmaceuticals, Inc. Sgc stimulators
BR112012024114B1 (pt) 2010-03-22 2021-02-09 Idorsia Pharmaceuticals Ltd Compostos derivados de 3-(heteroarilamino)-1,2,3,4-tetrahidro-9h-carbazol, uso dos mesmos, e, composição farmacêutica
KR20130112715A (ko) 2010-06-21 2013-10-14 오노 야꾸힝 고교 가부시키가이샤 4,4''-[4-플루오로-7-(｛4-[4-(3-플루오로-2-메틸페닐)부톡시]페닐｝에티닐)-2-메틸-1h-인돌-1,3-디일]디부탄산, 4,4''-[2-메틸-7-(｛4-[4-(펜타플루오로페닐)부톡시]페닐｝에티닐)-1h-인돌-1,3-디일]디부탄산 및 4,4''-[4-플루오로-2-메틸-7-(｛4-[4-(2,3,4,6-테트라플루오로페닐)부톡시]페닐｝에티닐)-1h-인돌-1,3-디일]디부탄산의 신규 결정형
DK2588465T3 (en) 2010-06-30 2017-05-01 Ironwood Pharmaceuticals Inc SGC stimulators
WO2012009134A1 (en) 2010-07-12 2012-01-19 Ironwood Pharmaceuticals, Inc. Crth2 modulators
WO2012009137A1 (en) 2010-07-12 2012-01-19 Ironwood Pharmaceuticals, Inc. Crth2 modulators
US9061030B2 (en) 2010-11-09 2015-06-23 Ironwood Pharmaceuticals, Inc. sGC stimulators
BR112013026283A8 (pt) 2011-04-14 2018-01-30 Actelion Pharmaceuticals Ltd derivados de ácido 7-(heteroaril-amino)-6,7,8,9-tetrahidropirido[1,2-a]indol acético e seu uso como moduladores do receptor d2 de prostaglandina
JP6054600B2 (ja) * 2011-08-11 2016-12-27 富士通コンポーネント株式会社 コネクタ
EP2790696A1 (en) 2011-12-16 2014-10-22 Atopix Therapeutics Limited Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
EP3112363A1 (en) 2011-12-27 2017-01-04 Ironwood Pharmaceuticals, Inc. 2-[1-[(2-fluorophenyl)methyl]-5-(3-isoxazolyl)-1h-pyrazol-3-yl]-pyrimidine derivatives and related compounds as soluble guanylate cyclase (sgc) stimulators for the treatment of pulmonary hypertension
CN108938441A (zh) 2012-03-21 2018-12-07 宾夕法尼亚大学理事会 用于调节毛发生长的组合物和方法
US9309235B2 (en) 2012-09-18 2016-04-12 Ironwood Pharmaceuticals, Inc. SGC stimulators
US9487508B2 (en) 2012-09-19 2016-11-08 Ironwood Pharmaceuticals, Inc. SGC stimulators
MX361208B (es) 2013-03-15 2018-11-30 Ironwood Pharmaceuticals Inc Estimuladores de guanilato ciclasa soluble (sgc).
EA032028B1 (ru) 2013-12-11 2019-03-29 Айронвуд Фармасьютикалз, Инк. СТИМУЛЯТОРЫ рГЦ
WO2015106268A1 (en) 2014-01-13 2015-07-16 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
SI3119779T1 (sl) 2014-03-17 2018-10-30 Idorsia Pharmaceuticals Ltd Derivati azaindolocetne kisline in njihova uporaba kot modulatorji prostaglandinskega receptorja D2
AU2015233046A1 (en) 2014-03-18 2016-11-03 Idorsia Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin D2 receptor modulators
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
CA2961489A1 (en) 2014-09-17 2016-03-24 Glen Robert RENNIE Sgc stimulators
WO2016044445A2 (en) 2014-09-17 2016-03-24 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
CA2959757A1 (en) 2014-09-17 2016-03-24 Ironwood Pharmaceuticals, Inc. Pyrazole derivatives as sgc stimulators
EP3328500B1 (en) 2015-07-30 2023-04-12 The Trustees of the University of Pennsylvania Single nucleotide polymorphic alleles of human dp-2 gene for detection of susceptibility to hair growth inhibition by pgd2 antagonists
WO2017046125A1 (en) 2015-09-15 2017-03-23 Actelion Pharmaceuticals Ltd Crystalline forms
MA45588A (fr) 2016-07-07 2019-05-15 Ironwood Pharmaceuticals Inc Formes solides d'un stimulateur de la gcs
EP3481837B1 (en) 2016-07-07 2023-12-06 Cyclerion Therapeutics, Inc. Phosphorus prodrugs of sgc stimulators
BR112022013784A2 (pt) 2020-01-13 2022-10-11 Durect Corp Sistemas de distribuição de fármacos de liberação prolongada com impurezas reduzidas e métodos relacionados

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US741360A (en) * 1899-11-13 1903-10-13 William M Moseley Toy.
BE790679A (fr) 1971-11-03 1973-04-27 Ici Ltd Derives de l'indole
JPH0615542B2 (ja) 1986-07-22 1994-03-02 吉富製薬株式会社 ピラゾロピリジン化合物
IL84796A (en) * 1986-12-17 1992-03-29 Merck Frosst Canada Inc Substituted n-benzyl-indoles and pharmaceutical compositions containing them
US5095031A (en) 1990-08-20 1992-03-10 Abbott Laboratories Indole derivatives which inhibit leukotriene biosynthesis
WO1993005020A1 (en) 1991-09-06 1993-03-18 Merck & Co., Inc. Indoles as inhibitors of hiv reverse transcriptase
CA2079374C (en) * 1991-09-30 2003-08-05 Merck Frosst Canada Incorporated (bicyclic-azaarylmethoxy)indoles as inhibitors of leukotriene biosynthesis
FR2692574B1 (fr) 1992-06-23 1995-06-23 Sanofi Elf Derives hydroxy-4 benzenethio, leur preparation ainsi que leur utilisation pour la preparation de derives aminoalkoxybenzenesulfonyles.
PL175788B1 (pl) 1993-02-24 1999-02-26 Merck & Co Inc Amidowe pochodne indolu i zawierające je kompozycje farmaceutyczne
US5486525A (en) * 1993-12-16 1996-01-23 Abbott Laboratories Platelet activating factor antagonists: imidazopyridine indoles
US5482960A (en) * 1994-11-14 1996-01-09 Warner-Lambert Company Nonpeptide endothelin antagonists
US5567711A (en) * 1995-04-19 1996-10-22 Abbott Laboratories Indole-3-carbonyl and indole-3-sulfonyl derivatives as platelet activating factor antagonists
TW472045B (en) 1996-09-25 2002-01-11 Astra Ab Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation
AR017256A1 (es) 1997-08-21 2001-09-05 American Home Prod Compuestos de indol sustituidos, metodo para la sintesis en fase solida de los mismos, conjuntos de combinacion para ser empleados en dicho metodo, uso delos compuestos para preparar un medicamento y composiciones farmaceuticas que los comprenden
CA2315226A1 (en) 1997-12-19 1999-07-01 Eli Lilly And Company Hypoglycemic imidazoline compounds
US6916841B2 (en) 1998-02-25 2005-07-12 Genetics Institute, Llc Inhibitors of phospholipase enzymes
AU5886500A (en) 1999-06-23 2001-01-09 Sepracor, Inc. Indolyl-benzimidazole antibacterials, and methods of use thereof
WO2001032621A1 (fr) 1999-10-29 2001-05-10 Wakunaga Pharmaceutical Co., Ltd. Nouveaux derives d'indole, et medicaments contenant lesdits derives comme principe actif
EP1263759B1 (en) 1999-12-24 2010-09-08 Aventis Pharma Limited Azaindoles
IL152682A0 (en) 2000-05-31 2003-06-24 Astrazeneca Ab Indole derivatives with vascular damaging activity
CN1245974C (zh) * 2000-06-28 2006-03-22 特瓦制药工业有限公司 卡维地洛
US6878522B2 (en) 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
SI1438289T1 (el) * 2001-09-27 2005-08-31 Hoffmann La Roche
TWI317634B (en) 2001-12-13 2009-12-01 Nat Health Research Institutes Aroyl indoles compounds
ATE340792T1 (de) 2002-02-01 2006-10-15 Hoffmann La Roche Substituierte indole als alpha-1 agonisten
SE0200356D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
EP2423190A1 (en) 2002-05-16 2012-02-29 Shionogi&Co., Ltd. Compounds Exhibiting PGD 2 Receptor Antagonism
SE0201635D0 (sv) * 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
SE0202463D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab Novel compounds
SE0301569D0 (sv) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
SE0302232D0 (sv) 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
US20070232681A1 (en) 2003-10-14 2007-10-04 Oxagen Limited Compounds Having Crth2 Antagonist Activity
SE0303180D0 (sv) 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
GB0500604D0 (en) 2005-01-13 2005-02-16 Astrazeneca Ab Novel process
GB2422831A (en) 2005-02-04 2006-08-09 Oxagen Ltd Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor
WO2007138282A2 (en) 2006-05-26 2007-12-06 Astrazeneca Ab Bi-aryl or aryl-heteroaryl substituted indoles
US20090318526A1 (en) 2006-06-08 2009-12-24 Uno Jacob Weber Use of cannabinoid receptor agonists as hypothermia inducing drugs for the treatment of ischemia
MX2008015768A (es) 2006-06-28 2009-01-07 Sanofi Aventis Nuevos inhibidores de cxcr2.

Also Published As

Publication number Publication date
US20100197756A1 (en) 2010-08-05
SI1551802T1 (sl) 2010-03-31
TW200404778A (en) 2004-04-01
NO20050828L (no) 2005-04-05
AR040498A1 (es) 2005-04-06
DE60330372D1 (de) 2010-01-14
PT1551802E (pt) 2010-02-02
EP1551802B1 (en) 2009-12-02
BR0312729A (pt) 2005-05-10
EP1551802A1 (en) 2005-07-13
JP2010280680A (ja) 2010-12-16
JP2011116770A (ja) 2011-06-16
US7723373B2 (en) 2010-05-25
ATE450506T1 (de) 2009-12-15
IL166121A0 (en) 2006-01-15
JP2005537265A (ja) 2005-12-08
ES2335491T3 (es) 2010-03-29
SE0203713D0 (sv) 2002-12-13
CY1109760T1 (el) 2014-09-10
AU2003251260B2 (en) 2007-04-26
NZ537606A (en) 2006-08-31
CN1678579A (zh) 2005-10-05
CN1279023C (zh) 2006-10-11
WO2004007451A1 (en) 2004-01-22
ZA200500170B (en) 2006-02-22
US20060111426A1 (en) 2006-05-25
JP4791729B2 (ja) 2011-10-12
AU2003251260A1 (en) 2004-02-02
CA2492445A1 (en) 2004-01-22
DK1551802T3 (da) 2010-03-15
MXPA05000646A (es) 2005-06-02

Similar Documents

Publication Publication Date Title
SE0202241D0 (sv) Novel Compounds
TW200407305A (en) Novel compounds
TW200510301A (en) Novel compounds
TW200510303A (en) Novel compounds
SE0303180D0 (sv) Novel compounds
SE0301010D0 (sv) Novel compounds
TW200612892A (en) Novel compounds
SE0301009D0 (sv) Novel compounds
MX2007011847A (es) Derivados de pirimidindiona como antagonistas del receptor de procineticina 2.
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
TW200732296A (en) Novel compounds
MY153719A (en) Prokineticin 1 receptor antagonists
MX2007011695A (es) Derivados de oxindol sustituido, medicamentos que contienen dichos derivados y uso de los mismos.
DE602006010738D1 (de) Pyrroloä2,3-cüpyridinderivate
MX2007011698A (es) Derivados de oxindol sustituido, medicamentos que contienen dichos derivados y uso de los mismos.
ATE467632T1 (de) Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors
TW200745039A (en) Isotopically substituted pantoprazole
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
UA106200C2 (uk) Заміщені похідні оксіндолу та їхнє застосування для лікування захворювань, залежних від вазопресину
DE60316128D1 (de) N-sulfonylurea-apoptosis-förderer
ATE486078T1 (de) 5,6-disubstituierte oxadiazolopyrazine und thiadiazolopyrazine als liganden des cxc- chemokinrezeptors
EA200602081A1 (ru) Пиридиновые производные алкилоксиндолов в качестве агентов, активных в отношении рецептора 5-нт7
EA200602080A1 (ru) Пиперазиновые производные алкилоксиндолов
UA84701C2 (ru) Замещенные индолы, способ их получения, их использования
SE0301798D0 (sv) New use IV